• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

Introduction to 1,3,4,6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose (CAS No. 56822-34-5) and Its Significance in Modern Research

The compound 1,3,4,6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose, identified by its CAS number 56822-34-5, represents a fascinating glycoside structure that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its intricate carbohydrate architecture, serves as a critical intermediate in the synthesis of complex glycosaminoglycans (GAGs) and glycoproteins, which are pivotal in numerous biological processes. The detailed acetylation and glycosylation patterns of this molecule make it a valuable tool for investigating the structural and functional roles of carbohydrates in cellular communication and disease mechanisms.

Recent advancements in glycobiology have highlighted the importance of carbohydrate-based therapeutics, particularly in the development of antiviral, anti-inflammatory, and anticancer agents. The structure of 1,3,4,6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose provides a scaffold that can be modified to explore novel pharmacological interactions. For instance, studies have demonstrated that modifications at the 1,3,4,6-Tetra-O-acetyl positions can influence the solubility and reactivity of the glycoside, making it an ideal candidate for conjugation with other biomolecules or for use in controlled-release systems.

One of the most compelling aspects of this compound is its potential application in drug design. Carbohydrates are known to play a crucial role in cell signaling and recognition processes, and alterations in their structure can lead to significant changes in biological activity. The 1,3,4,6-Tetra-O-acetyl modification enhances the stability of the glycoside core while maintaining its ability to interact with specific enzymes or receptors. This balance is essential for developing glycosidic drugs that are both effective and biocompatible.

In clinical research, derivatives of 1,3,4,6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose have been explored for their potential therapeutic benefits. For example, modifications aimed at enhancing binding affinity to specific lectins or enzymes have shown promise in preclinical models of inflammation and cancer. The 2-(α-L-fucopyranosyl) moiety is particularly noteworthy, as fucosylated glycans are abundant in natural glycoproteins and are involved in various physiological processes. By studying compounds like this one, researchers can uncover new insights into how carbohydrate structures modulate disease pathways.

The synthesis of 1,3,4,6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose is also an area of active investigation. Advances in synthetic chemistry have enabled more efficient and scalable production methods for complex glycosides. These methods often involve multi-step reactions that require precise control over stereochemistry and regioselectivity. The development of such synthetic routes not only facilitates research but also opens up new possibilities for industrial applications where high-purity carbohydrates are needed.

From a broader perspective, the study of compounds like 1,3,4,6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose contributes to our understanding of carbohydrate chemistry at a fundamental level. This knowledge is essential for designing new biomimetic materials or for developing synthetic vaccines that mimic natural carbohydrate antigens. Such applications could revolutionize immunotherapy by providing targeted treatments with minimal side effects.

The role of carbohydrates as drug candidates has been further underscored by recent discoveries linking aberrant glycosylation to various diseases. For instance，researchers have identified that changes in glycan patterns can be indicative of metabolic disorders or cancer progression. By leveraging compounds like 1，3，4，6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose, scientists can develop diagnostic tools or therapeutic agents that specifically target these altered glycans.

In summary，the compound 1，3，4，6-Tetra-O-acetyl-2-(α-L-fucopyranosyl)-α-D-galactopyranose (CAS No. 56822-34-5) is a cornerstone in modern glycobiological research。 Its unique structural features make it a versatile tool for exploring carbohydrate function，drug design，and synthetic applications。 As our understanding of carbohydrates continues to evolve，compounds like this one will undoubtedly play an increasingly important role in advancing both basic science and clinical therapeutics.

• 604-68-2([(2R,3R,4S,5R,6R)-3,4,5,6-tetrakis(acetyloxy)oxan-2-yl]methyl acetate)
• 22352-19-8(Octaacetyl-β-maltose)
• 4163-60-4([(2R,3S,4S,5R,6S)-3,4,5,6-tetrakis(acetyloxy)oxan-2-yl]methyl acetate)
• 18968-05-3(1,3,4,6-Tetra-O-acetyl-b-D-mannopyranose)
• 5346-90-7(α-D-Cellobiose octaacetate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)